About Dpb Antibiotics Private Limited
Data last updated: 21 December 2025
Dpb Antibiotics Private Limited is a private limited company based in Chandigarh, Chandigarh, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 27 March 2010, the company has been in operation for over 16 years.
Registered with ROC Chandigarh under CIN U51397MH2010PTC201353.
Capital: an authorised share capital of ₹2 Cr and a paid-up capital of ₹10 Lakh. It is led by directors including Devang Manharlal Ajmera and Piyush Manharlal Ajmera.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Plot No 73 Industrial Area, Phase 2, Chandigarh, Chandigarh, India – 160002.
As per the financials filed for FY 2024, the company reported a revenue of ₹10,000, a decline of 100% compared to the previous year.
Its group structure includes 1 subsidiary.
The company is associated with 2 brands - Vardhman Chemtech, Dpb Group.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dpbpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No 73 Industrial Area, Phase 2, Chandigarh, Chandigarh, India – 160002
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited has one previous CIN (Corporate Identification Number): U51397MH2010PTC201353. The current CIN is U51397CH2010PTC046352, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U51397CH2010PTC046352 | Current |
| U51397MH2010PTC201353 | Previous |
Associated Brands with Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited operates two associated brands: Vardhman Chemtech and DPB Group. These brands represent Dpb Antibiotics Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of bulk drugs, intermediates and fine chemicals | vardhmanchemtech.com | |
| DPB Group is engaged in manufacturing pharmaceutical APIs in India. | dpbpharma.com |
Competitors & Alternatives of Dpb Antibiotics Private Limited
Brands and companies operating in the same space as Dpb Antibiotics Private Limited include Laurus Labs, Symbiotec, WuXi AppTec and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
ANI Pharmaceuticals
|
Branded and generic prescription drugs are developed, manufactured, and marketed. | Baudette, United States, United States | 1996 |
Aptar
|
Regulatory support, brand differentiation, and prototyping services are provided. | Crystal Lake, United States, United States | 1992 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Red Nucleus
|
Advisory, scientific, and medical communications provided for pharmaceutical industry. | Yardley, United States, United States | 2014 |
Ipsen
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 1929 |
Eurofins Scientific
|
Laboratory testing and contract research services are provided globally. | Luxembourg, Luxembourg, Luxembourg | 1987 |
Auditor Details of Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited is audited by Jayshree Jain for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Jayshree Jain | blur-value | blur-value | blur-value |
Board of Directors of Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited is currently managed by 4 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Devang Manharlal Ajmera | Director | 27 Mar 2010 | 16 Years 3 Months | Current |
|
Piyush Manharlal Ajmera
Also directs:
Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited
|
Director | 27 Mar 2010 | 16 Years 3 Months | Current |
|
Bhavin Manharlal Ajmera
Also directs:
Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited
|
Director | 27 Mar 2010 | 16 Years 3 Months | Current |
| Sharvan Bhatt | Additional Director | 03 Nov 2025 | 0 Years 8 Months | Current |
Financials of Dpb Antibiotics Private Limited FY 2024 filings available
Dpb Antibiotics Private Limited reported revenue of ₹10,000 (down 100% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Dpb Antibiotics Private Limited
As of FY 2023, Dpb Antibiotics Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Dpb Antibiotics Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Vardhman Chemtech Limited | U24117CH1996PLC018656 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Dpb Antibiotics Private Limited
View historical data on people associated with Dpb Antibiotics Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Dpb Antibiotics Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Dpb Antibiotics Private Limited
GSTIN & GST Filing Data of Dpb Antibiotics Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Dpb Antibiotics Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Dpb Antibiotics Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Dpb Antibiotics Private Limited
MSME Payment Delays by Dpb Antibiotics Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Dpb Antibiotics Private Limited
Subsidiaries & Group Companies of Dpb Antibiotics Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Dpb Antibiotics Private Limited with ownership details.
MCA Filings & Documents of Dpb Antibiotics Private Limited
MCA Filings & Documents of Dpb Antibiotics Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Dpb Antibiotics Private Limited
Frequently Asked Questions about Dpb Antibiotics Private Limited
Dpb Antibiotics Private Limited is an active private limited company in the pharma sector based in Chandigarh, Chandigarh, India. It was incorporated on 27 March 2010 (16+ years old) and is registered under CIN U51397CH2010PTC046352.
Dpb Antibiotics Private Limited reported revenue of ₹10,000 for FY 2024 (down 100.00% YoY).
The current directors of Dpb Antibiotics Private Limited are:
The primary industry of Dpb Antibiotics Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Dpb Antibiotics Private Limited can be reached at the registered office: Plot No 73 Industrial Area, Phase 2, Chandigarh, Chandigarh, India – 160002, or through the website dpbpharma.com.
The authorised capital is ₹2 Cr, and the paid-up capital is ₹10 Lakh.